Does adding facilitated behaviour change improve outcomes for people with recently diagnosed diabetes?

Conditions

Diabetes Nutritional, Metabolic, Endocrine Non-insulin-dependent diabetes mellitus

Hajira Dambha‐Miller, Andrew Cooper, Rebecca K. Simmons, Ann Louise Kinmonth, Simon J. Griffin

BMJ Open2016-01-017 citations

10.1136/bmjopen-2015-008931

Which Behavior Change Techniques are Associated with Changes in Physical Activity, Diet and Body Mass Index in People with Recently Diagnosed Diabetes?

Nelli Hankonen, Stephen Sutton, A Toby Prevost, Rebecca K. Simmons, Simon J. Griffin et al. (7 authors)

Annals of Behavioral Medicine2014-05-07141 citations

10.1007/s12160-014-9624-9

Multiple behaviour change intervention and outcomes in recently diagnosed type 2 diabetes: the ADDITION-Plus randomised controlled trial.

Griffin SJ, Simmons RK, Prevost AT, Williams KM, Hardeman W, Sutton S, Brage S, Ekelund U, Parker RA, Wareham NJ, Kinmonth AL, ADDITION-Plus study team.

2014-04-2428 citations

10.1007/s00125-014-3236-6

Association between objectively assessed sedentary time and physical activity with metabolic risk factors among people with recently diagnosed type 2 diabetes

Andrew Cooper, Søren Brage, Ulf Ekelund, Nicholas J. Wareham, Simon J. Griffin et al. (6 authors)

Diabetologia2013-10-01115 citations

10.1007/s00125-013-3069-8

Are people with negative diabetes screening tests falsely reassured? Parallel group cohort study embedded in the ADDITION (Cambridge) randomised controlled trial.

Paddison CA, Eborall HC, Sutton S, French DP, Vasconcelos J, Prevost AT, Kinmonth AL, Griffin SJ.

2009-11-3027 citations

10.1136/bmj.b4535

Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial.

Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S.

2007-08-3095 citations

10.1136/bmj.39303.723449.55

Interventions

Recruited practices have been randomised to screening for diabetes followed by Routine Care (RC) according to national guidelines or screening followed by Intensive multifactorial intervention (I). We

Eligibility

Sex/Gender

All

Inclusion criteria

Inclusion criteria: Patients aged 40-69 with a diabetes risk score more than or equal to 0.17 (representing the top 25% of risk distribution) are invited for a random capillary screening test for diabetes. Patients are eligible to take part if the diagnosis of diabetes is confirmed by subsequent fasting capillary test and oral glucose tolerance test. Following the funded extension, inclusion criteria extended to include patients aged 40 to 69 years with type 2 diabetes diagnosed within the last 3 years.

Exclusion criteria

Exclusion criteria: Potential participants are excluded if they are pregnant or lactating, have a psychotic illness or have an illness with a likely prognosis of less than 1 year.

Design outcomes

Primary

Measure	Time frame
The principal comparisons between I1 and I2 include changes in weight, self-reported physical activity (IPAQ, EPAQ2), diet (Food Frequency Questionnaire), medication adherence (MARS), smoking status and differences at 1 year in objectively measured physical activity (PAR, CSA [accelerometer]), diet (plasma vitamin C) and medication adherence (plasma drug levels). A cross domain measure of behaviour change at 1 year is under development. Modelled 5-year risk of cardiovascular events, incorporating glycaemia, blood pressure and lipid levels, represents the main outcome for the trial of intensive treatment (RC vs I). In addition, we propose to assess at all levels along our causal pathway psychological measures (illness perceptions, attitudes and intentions towards targeted healthy behaviours), anthropometric variables (weight, body fat distribution and waist circumference) and biochemical parameters (HbA1c, cholesterol and albumin/creatinine ratio).	—

Measure

Time frame

The principal comparisons between I1 and I2 include changes in weight, self-reported physical activity (IPAQ, EPAQ2), diet (Food Frequency Questionnaire), medication adherence (MARS), smoking status and differences at 1 year in objectively measured physical activity (PAR, CSA [accelerometer]), diet (plasma vitamin C) and medication adherence (plasma drug levels). A cross domain measure of behaviour change at 1 year is under development. Modelled 5-year risk of cardiovascular events, incorporating glycaemia, blood pressure and lipid levels, represents the main outcome for the trial of intensive treatment (RC vs I). In addition, we propose to assess at all levels along our causal pathway psychological measures (illness perceptions, attitudes and intentions towards targeted healthy behaviours), anthropometric variables (weight, body fat distribution and waist circumference) and biochemical parameters (HbA1c, cholesterol and albumin/creatinine ratio).

—

Secondary

Measure	Time frame
No secondary outcome measures	—

Countries

United Kingdom

Outcome results

None listed